Continuous infusion of beta-lactams: a blissful option for the intensive care unit
- PMID: 28149601
- PMCID: PMC5227275
- DOI: 10.21037/jtd.2016.12.47
Continuous infusion of beta-lactams: a blissful option for the intensive care unit
Conflict of interest statement
MD Zilberberg has received consulting fees and/or research funding from Astellas, Pfizer, The Medicines Company, Merck, Shionogi, Tetraphase, Theravance, Melinta and Achaogen. AF Shorr serves as a consultant to, speaker for, or received research support from Achaogen, Astellas, Bayer, Cempra, The Medicines Company, Melinta, Merck, Paratek, Pfizer, Shionogi, Tetraphase, Theravance.
Comment on
-
Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.Intensive Care Med. 2016 Oct;42(10):1535-1545. doi: 10.1007/s00134-015-4188-0. Epub 2016 Jan 11. Intensive Care Med. 2016. PMID: 26754759 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources